AstraZeneca PLC (AZN)

Price$179.71

Value ScoreD

Growth ScoreB

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-14.82%

Price vs S&P 500 (4W)-6.02%

VGM Score51.77

Market Capitalization$214.05B

P/E Ratio (Annual)28.19x

Indicated Dividend Yield (Annual)1.78%

All Metrics

P/CF (Annual)19.77x

Book Value / Share (Quarterly)$30.52

P/TBV (Annual)26.52x

Indicated Dividend (Annual)$236.20

Revenue Growth (3Y)9.82%

Cash Flow / Share (Quarterly)$4.99

Payout Ratio (TTM)47.27%

Price vs S&P 500 (YTD)-10.85%

Gross Margin (TTM)81.42%

Net Profit Margin (TTM)17.19%

EPS (TTM)$6.65

10-Day Avg Trading Volume1.22M

EPS Excl Extra (TTM)$6.65

Revenue Growth (5Y)17.15%

EPS (Annual)$6.55

Dividend / Share (Annual)$3.21

ROI (Annual)13.06%

Gross Margin (Annual)81.63%

Net Profit Margin (5Y Avg)10.23%

Cash / Share (Quarterly)$4.95

P/E Basic Excl Extra (TTM)27.74x

Revenue Growth QoQ (YoY)12.51%

EPS Growth (5Y)21.88%

P/E Normalized (Annual)28.19x

ROA (Last FY)8.96%

Revenue Growth TTM (YoY)9.93%

EBITD / Share (TTM)$11.79

ROE (5Y Avg)12.53%

Operating Margin (TTM)23.69%

Cash Flow / Share (Annual)$5.59

P/B Ratio6.09x

P/B Ratio (Quarterly)6.48x

Net Income / Employee (Annual)$106,400

EV / Revenue (TTM)5.20x

Net Interest Coverage (TTM)12.68x

ROA (TTM)9.13%

EPS Growth QoQ (YoY)5.63%

EV / EBITDA (TTM)17.09x

EPS Incl Extra (Annual)$6.55

Current Ratio (Annual)0.94x

Quick Ratio (Quarterly)0.71x

3-Month Avg Trading Volume1.36M

52-Week Price Return30.53%

EV / Free Cash Flow (Annual)36.28x

P/E Incl Extra (TTM)27.74x

Revenue / Employee (TTM)$628,900

Tangible BV / Share (Quarterly)$6.72

P/S Ratio (Annual)4.91x

Asset Turnover (Annual)0.51x

52-Week High$15730.00

Operating Margin (5Y Avg)14.21%

EPS Excl Extra (Annual)$6.55

CapEx CAGR (5Y)17.77%

Tangible BV CAGR (5Y)-2.48%

26-Week Price Return1.11%

Quick Ratio (Annual)0.66x

13-Week Price Return-9.94%

Total Debt / Equity (Annual)0.61x

Current Ratio (Quarterly)0.91x

Enterprise Value$314.56B

Revenue / Share Growth (5Y)13.15%

Asset Turnover (TTM)0.53x

Book Value / Share Growth (5Y)21.40%

Revenue / Employee (Annual)$611,200

Inventory Turnover (Annual)1.82x

Pretax Margin (Annual)21.11%

Cash / Share (Annual)$3.70

3-Month Return Std Dev23.77%

Gross Margin (5Y Avg)80.23%

Net Income / Employee (TTM)$108,100

EBITDA CAGR (5Y)20.34%

EBITDA Interim CAGR (5Y)18.02%

ROE (Last FY)21.01%

Net Interest Coverage (Annual)10.22x

EPS Basic Excl Extra (Annual)$6.55

P/FCF (TTM)37.20x

Receivables Turnover (TTM)4.42x

EV / Free Cash Flow (TTM)40.60x

Total Debt / Equity (Quarterly)0.72x

EPS Incl Extra (TTM)$6.65

Receivables Turnover (Annual)5.67x

ROI (TTM)13.17%

Dividend Growth Rate (5Y)3.33%

P/S Ratio (TTM)4.77x

Pretax Margin (5Y Avg)11.43%

Revenue / Share (Annual)$37.60

Tangible BV / Share (Annual)$6.98

Forward P/E17.28x

Free OCF CAGR (5Y)31.64%

Price vs S&P 500 (52W)2.32%

P/E Ratio (TTM)27.74x

EPS Growth TTM (YoY)33.71%

Year-to-Date Return0.09%

5-Day Price Return-0.82%

EPS Normalized (Annual)$6.55

ROA (5Y Avg)5.03%

Net Profit Margin (Annual)17.41%

Month-to-Date Return-1.05%

Cash Flow / Share (TTM)$5.82

EBITD / Share (Annual)$11.41

EPS Growth (3Y)45.90%

Operating Margin (Annual)23.40%

LT Debt / Equity (Annual)0.51x

P/CF (TTM)20.27x

ROI (5Y Avg)7.37%

P/E Excl Extra (TTM)27.74x

LT Debt / Equity (Quarterly)0.52x

EPS Basic Excl Extra (TTM)$6.65

P/TBV (Quarterly)29.43x

Payout Ratio (Annual)48.62%

P/B Ratio (Annual)5.90x

Dividend / Share (TTM)$3.17

Inventory Turnover (TTM)1.80x

Pretax Margin (TTM)21.37%

Book Value / Share (Annual)$31.38

Price vs S&P 500 (13W)-19.69%

Net Margin Growth (5Y)7.71%

Dividend Yield (TTM)1.70%

Beta1.29x

P/FCF (Annual)33.24x

Revenue / Share (TTM)$38.72

ROE (TTM)22.27%

52-Week Low$10104.00

vGradeD

gGradeB

mGradeC

vgmGradeC

Show chart for

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.15

4.08

4.14

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
AZNAstraZeneca PLC	D	B	C	$179.71
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64
VRTXVertex Pharmaceuticals Inc	D	B	C	$438.40

About

AstraZeneca is a multinational pharmaceutical company formed in 1999 through the merger of Sweden's Astra and UK-based Zeneca. The company develops and markets branded drugs across oncology (over 40% of revenue), cardiovascular and metabolic diseases (20%+), rare diseases, and respiratory and immunology. Its revenue is geographically diversified, with approximately one-third of sales derived from the United States and the remainder from international markets.